Compound Identification and Natural Sources

Common name: Apigenin

IUPAC name: 4’,5,7-trihydroxyflavone (5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one)

CAS Registry Number: 520-36-5

Molecular formula: C₁₅H₁₀O₅

Molecular weight: 270.24 g/mol

Chemical class: Flavone (subclass of flavonoids)

Apigenin is among the most widely distributed plant flavonoids. Its primary dietary source is chamomile (Matricaria chamomilla, syn. Matricaria recutita), where it occurs as the glycoside apigenin-7-O-glucoside and in free form. Additional sources include parsley (Petroselinum crispum), celery (Apium graveolens), dried oregano, thyme, and various citrus fruits. Chamomile tea, one of the most consumed herbal beverages worldwide, delivers apigenin as the dominant bioactive flavonoid. Standardized chamomile extracts used in clinical research typically contain 1.0–1.2% apigenin by weight.

Apigenin has a long history of human consumption as a dietary flavonoid with a well-characterized safety profile. It is commercially available as a purified supplement (typical doses: 50 mg capsules) and as a component of standardized chamomile extracts.

Therapeutic Indication and Application

This disclosure covers the following therapeutic applications of apigenin, individually and in combination:

Primary indication — Anxiolytic use: Oral administration of apigenin for the reduction of anxiety symptoms in adults, acting via GABAergic mechanisms to produce anxiolysis without the sedation, muscle relaxation, cognitive impairment, or dependence risk associated with classical benzodiazepine drugs.

Secondary indication — Sleep promotion: Oral administration of apigenin for the promotion of sleep onset and improvement of sleep quality in adults with insomnia or sleep disturbance, acting through GABA-A receptor modulation, reduction of neuroinflammatory markers (TNF-alpha, IL-6), modulation of serotonin (a melatonin precursor), and upregulation of brain-derived neurotrophic factor (BDNF).

Combination use — Apigenin plus magnesium: Co-administration of apigenin with magnesium salts (magnesium glycinate, magnesium citrate, magnesium threonate, or other bioavailable magnesium forms) for synergistic sleep-promoting effects, as demonstrated in preclinical models showing 32–44% improvements in sleep duration across normal, caffeine-disturbed, and insomnia-model mice (Food & Function, 2026; DOI: 10.1039/D5FO04538J).

Target population: Adults (age 18+) with generalized anxiety, situational anxiety, chronic primary insomnia, sleep-onset difficulty, or poor sleep quality. Not indicated for acute psychiatric emergencies, seizure disorders, or as a replacement for prescribed benzodiazepines in patients with established benzodiazepine dependence.

Mechanism of Action

Apigenin exerts its anxiolytic and sleep-promoting effects through multiple convergent pathways centered on GABAergic neurotransmission:

Benzodiazepine binding site interaction. Apigenin competitively binds the benzodiazepine binding site on GABA-A receptors with a Ki of 4 microM, as demonstrated by competitive displacement of [³H]flunitrazepam in rat brain cortical membranes (Viola et al., Planta Medica, 1995, 61:213–216; PMID: 7617761). This binding is flumazenil-sensitive, confirming interaction at the classical benzodiazepine site rather than a non-specific effect. Apigenin showed no measurable affinity for muscarinic cholinergic receptors or alpha-1 adrenergic receptors, indicating selectivity for the GABAergic target.

Positive allosteric modulation of GABA-A receptors. Apigenin functions as a positive allosteric modulator (PAM) of the GABA-A receptor-chloride ionophore complex. At recombinant human alpha-1/beta-2/gamma-2L GABA-A receptors expressed in Xenopus laevis oocytes, apigenin exhibits a novel “second-order” modulatory action: it enhances the positive modulation by diazepam of GABA-mediated chloride currents (Campbell et al., Biochemical Pharmacology, 2004, 68(8):1631–1638; PMID: 15451406). The IC50 for direct GABA activation inhibition at these recombinant receptors is 8 microM, but the clinically relevant action is the potentiation of the endogenous GABA signaling cascade rather than direct agonism.

Subunit-selective pharmacology. At flumazenil-insensitive alpha-1/beta-2 receptors (lacking the gamma-2 subunit), apigenin acts as a GABA antagonist, indicating that its positive modulatory effects require the gamma-2 subunit — the same subunit required for benzodiazepine binding. This subunit selectivity profile distinguishes apigenin from broad-spectrum GABA-A agonists and contributes to its favorable side-effect profile (Campbell et al., 2004).

Partial agonist/low-efficacy profile. Unlike full benzodiazepine agonists (diazepam, alprazolam, midazolam), apigenin produces anxiolytic effects at standard doses without sedation, muscle relaxation, or anticonvulsant activity (Viola et al., 1995). Only at 10-fold higher concentrations does mild sedation emerge (26% reduction in ambulatory activity, 35% reduction in hole-board exploration parameters). This profile is consistent with a partial agonist or low-efficacy modulator at the benzodiazepine site — precisely the pharmacological profile associated with reduced dependence liability and abuse potential relative to full benzodiazepine agonists.

Anti-inflammatory and neurotrophic contributions to sleep. Beyond direct GABAergic effects, apigenin reduces circulating TNF-alpha and IL-6, proinflammatory cytokines implicated in sleep disruption (Frontiers in Nutrition, 2024; DOI: 10.3389/fnut.2024.1359176). Apigenin increases BDNF expression and elevates serotonin levels — serotonin being the direct metabolic precursor to melatonin via the serotonin-N-acetyltransferase and hydroxyindole-O-methyltransferase pathway. These pleiotropic effects create a multi-target sleep-promoting mechanism distinct from single-target hypnotics.

CD38 inhibition and NAD+ preservation. Apigenin inhibits CD38, a major NAD+-consuming ectoenzyme. By preserving cellular NAD+ pools, apigenin may support circadian clock gene function (CLOCK, BMAL1) that depends on NAD+-dependent sirtuins (SIRT1), providing an additional mechanism linking apigenin to sleep-wake cycle regulation (Frontiers in Nutrition, 2024).

Dosing Protocols from Published Literature

The following dosing protocols are documented in published peer-reviewed literature and are disclosed here as prior art:

Protocol 1 — Standardized chamomile extract for insomnia (clinical trial):

  • Form: Standardized chamomile extract (Matricaria recutita), containing approximately 1.2% apigenin
  • Dose: 270 mg extract, twice daily (540 mg total daily; approximately 5.4–6.5 mg apigenin/day)
  • Route: Oral
  • Duration: 28 days
  • Population: Adults 18–65 with DSM-IV chronic primary insomnia (greater than or equal to 6 months duration)
  • Source: Zick et al., BMC Complementary and Alternative Medicine, 2011, 11:78 (PMID: 21939549; PMC3198755)
  • Outcomes: Modest improvements in daytime functioning; moderate effect sizes for sleep latency and nighttime awakenings favoring chamomile; no significant adverse events

Protocol 2 — Purified apigenin supplement for sleep (widely used consumer protocol):

  • Form: Purified apigenin (synthetic or plant-derived)
  • Dose: 50 mg
  • Route: Oral
  • Timing: 30–60 minutes before intended sleep
  • Duration: Ongoing nightly use
  • Note: This protocol is widely disseminated and commercially available but has not been evaluated in a published randomized controlled trial with isolated apigenin at this dose as of April 2026. It is included as prior art due to extensive public use and commercial availability.

Protocol 3 — Apigenin plus magnesium synergistic combination (preclinical):

  • Form: Apigenin combined with magnesium salt (glycinate, citrate, or threonate)
  • Evidence basis: Animal models demonstrating synergistic sleep-promoting effects with 44% improvement in sleep duration in normal mice, 32% in caffeine-disturbed mice, and 37% in insomnia-model mice
  • Source: Food & Function, 2026 (DOI: 10.1039/D5FO04538J)
  • Proposed human protocol (extrapolated, not clinically validated): 50 mg apigenin + 200–400 mg elemental magnesium, oral, 30–60 minutes before sleep

Protocol 4 — Chamomile tea for sleep and mood (clinical observation):

  • Form: Chamomile tea (aqueous infusion)
  • Dose: One to two cups daily
  • Population: Postpartum women
  • Duration: 2 weeks
  • Source: Chang & Chen, 2016
  • Outcomes: Improved sleep quality and reduced postpartum depression symptoms

Prior Art and Published Evidence

The following studies constitute the published scientific literature establishing apigenin’s GABAergic anxiolytic and sleep-promoting properties:

Foundational receptor binding and anxiolytic studies:

  1. Viola, H., Wasowski, C., Levi de Stein, M., et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. PMID: 7617761. — Established apigenin as a benzodiazepine receptor ligand (Ki = 4 microM) with anxiolytic activity in mice without sedation at standard doses.

  2. Campbell, E. L., Chebib, M., & Johnston, G. A. R. (2004). The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical Pharmacology, 68(8), 1631–1638. PMID: 15451406. — Demonstrated apigenin’s second-order positive allosteric modulation at alpha-1/beta-2/gamma-2L GABA-A receptors and subunit-dependent pharmacology.

  3. Wasowski, C., & Marder, M. (2012). Flavonoids as GABA(A) receptor ligands: the whole story? British Journal of Pharmacology, 168(5), 998–1024. PMC4863311. — Comprehensive review of flavonoid interactions with GABA-A receptors, including apigenin binding data and structure-activity relationships.

  4. Johnston, G. A. R. (2005). GABA(A) receptor channel pharmacology. Current Pharmaceutical Design, 11(15), 1867–1885. — Review covering flavonoid modulation of GABA-A receptor subtypes.

Clinical sleep and insomnia studies:

  1. Zick, S. M., Wright, B. D., Sen, A., & Arnedt, J. T. (2011). Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine, 11:78. PMID: 21939549; PMC3198755. — RCT of 270 mg chamomile extract BID in 34 insomnia patients showing modest sleep benefits.

  2. Chang, S. M., & Chen, C. H. (2016). Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women: a randomized controlled trial. Journal of Advanced Nursing, 72(2), 306–315. — Chamomile tea improved sleep and mood in postpartum women.

  3. Godos, J., Ferri, R., Castellano, S., et al. (2020). Dietary polyphenol intake and sleep quality in a Mediterranean cohort. Nutrients, 12(5), 1226. — Cross-sectional study correlating dietary apigenin intake with better sleep quality in Italian adults.

Mechanistic reviews — sleep pathways:

  1. Shinjyo, N., Waddell, G., & Green, J. (2024). Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition, 11:1359176. PMC10929570. — Review of apigenin’s multi-target sleep-promoting mechanisms including GABA modulation, anti-inflammatory effects, BDNF upregulation, serotonin elevation, and CD38 inhibition.

Synergistic combination studies:

  1. [Authors]. (2026). Synergistic sleep-promoting effects of magnesium and apigenin in normal and insomnia mouse models. Food & Function (RSC Publishing). DOI: 10.1039/D5FO04538J. — Demonstrated 32–44% improvements in sleep duration with apigenin-magnesium combination across multiple mouse models.

Bioassay-guided isolation:

  1. Avallone, R., Zanoli, P., Puia, G., et al. (2000). Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology, 59(11), 1387–1394. — Bioassay-guided isolation confirming apigenin as the active GABAergic component in chamomile.

  2. Jager, A. K., Gauguin, B., Andersen, J., et al. (2006). Bioassay-guided isolation of apigenin with GABA-benzodiazepine activity from Tanacetum parthenium. Phytotherapy Research, 20(1), 1003–1005. — Independent confirmation of apigenin’s GABA-benzodiazepine activity from a separate plant source.

Patent Landscape Analysis

A review of the existing patent landscape relevant to apigenin’s anxiolytic and sleep-promoting applications reveals the following:

WO1995005169A1 — “Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity.” Filed 1993 by The University of Strathclyde. Covers flavonoid derivatives broadly for anxiolytic use. This patent has expired (filed 1993, more than 20 years ago). It addresses synthetic flavonoid derivatives rather than apigenin specifically for sleep or anxiolytic use via GABA-A modulation.

US9056209B2 — “Apigenin-containing composition.” Filed 2010 by Kao Corporation. Granted 2015, status: expired (fee-related). This patent covers apigenin-containing compositions for dermatological (skin whitening/bleaching) applications under A61Q19/02 classification — it does not claim anxiolytic, sleep-promoting, or GABA-modulatory therapeutic uses.

US20120213842A1 — “Methods of making and using compositions comprising flavonoids.” Filed 2012. Covers methods for manufacturing flavonoid compositions including apigenin. Focuses on formulation and manufacturing methods, not specific therapeutic GABAergic applications.

US20070122495A1 — “Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative.” Covers multi-herb compositions for anxiolytic effects. Does not claim isolated apigenin or its specific GABA-A mechanism.

WO1995025514A1 — “Compounds useful as anxiolytic, sedative, and hypnotic agents.” Filed 1995. Covers tryptamine derivatives, not flavonoids or apigenin.

Gap identified: No granted, in-force patent specifically claims the use of apigenin (isolated or as a characterized component of chamomile extract) for anxiolytic and/or sleep-promoting effects mediated by positive allosteric modulation of GABA-A receptors at the benzodiazepine binding site. This disclosure is intended to prevent such claims from being patentable by establishing enabling prior art in the public domain.

Enablement Statement

This disclosure provides sufficient detail for a person of ordinary skill in the art (a pharmacologist, sleep medicine researcher, or nutraceutical formulation scientist) to practice the disclosed therapeutic applications without undue experimentation:

  • Compound identification is unambiguous: apigenin, CAS 520-36-5, C₁₅H₁₀O₅, commercially available from multiple suppliers (Sigma-Aldrich, TCI, Cayman Chemical) at greater than or equal to 95% purity, and as a component of standardized chamomile extracts (1.0–1.2% w/w).
  • Mechanism is described with specific receptor binding data (Ki = 4 microM at benzodiazepine site; IC50 = 8 microM at alpha-1/beta-2/gamma-2L GABA-A receptors), subunit requirements (gamma-2 required for positive modulation), and downstream signaling pathways.
  • Dosing protocols are provided from published human clinical trials (270 mg standardized chamomile extract BID = approximately 5.4 mg apigenin/day) and widely available commercial products (50 mg purified apigenin, 30–60 minutes before sleep).
  • Outcome measures are specified: anxiolytic effect measured by elevated plus-maze (preclinical) and validated anxiety scales (clinical); sleep effect measured by sleep diary, Pittsburgh Sleep Quality Index (PSQI), sleep latency, WASO, and Fatigue Severity Scale.
  • Safety data from clinical trials shows no significant adverse events relative to placebo at the described doses.
  • Combination protocols (apigenin + magnesium) are described with preclinical efficacy data and proposed human translation doses.

A practitioner reading this disclosure can: (1) source the compound, (2) prepare the formulation at the specified doses, (3) administer it by the specified route and schedule, (4) measure outcomes using the specified instruments, and (5) interpret results in the context of the described mechanism.

Public Domain Dedication and Defensive Purpose

This disclosure is published as a defensive publication under the Pubroot prior-art framework. Its sole purpose is to establish dated, enabling, publicly accessible prior art that anticipates potential method-of-use patent claims on apigenin for anxiolytic and sleep-promoting effects via GABA-A receptor modulation.

All information in this disclosure is placed into the public domain. No patent rights are claimed or reserved by the author. This disclosure is intended to be freely used, reproduced, and cited by anyone for any purpose, including but not limited to:

  • Citation as prior art in patent examination proceedings before the USPTO, EPO, WIPO, or any national patent office
  • Use in inter partes review (IPR), post-grant review (PGR), or ex parte reexamination proceedings
  • Use by patent examiners during prosecution to reject claims under 35 U.S.C. Section 102 (anticipation) or Section 103 (obviousness)
  • Use by any person, company, or institution to manufacture, sell, or distribute apigenin-containing products for anxiolytic or sleep-promoting purposes without patent restriction

Explicit dedication: To the extent permitted by law, this work is dedicated to the public domain under CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The author waives all copyright and related rights to this work. Where not legally possible, the author grants an irrevocable, unconditional license to use this work for any purpose.

Date of publication: April 2026, via Pubroot (pubroot.com), with verifiable Git commit timestamp.

This is not medical advice. This disclosure describes published scientific findings and is intended as a patent defense document. It does not constitute a recommendation to use apigenin for any therapeutic purpose. Individuals should consult qualified healthcare providers before using apigenin or any supplement for anxiety or sleep conditions.

References

  1. Viola, H., Wasowski, C., Levi de Stein, M., et al. (1995). Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Medica, 61(3), 213–216. PMID: 7617761.
  2. Campbell, E. L., Chebib, M., & Johnston, G. A. R. (2004). The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical Pharmacology, 68(8), 1631–1638. PMID: 15451406.
  3. Wasowski, C., & Marder, M. (2012). Flavonoids as GABA(A) receptor ligands: the whole story? British Journal of Pharmacology, 168(5), 998–1024. PMC4863311.
  4. Zick, S. M., Wright, B. D., Sen, A., & Arnedt, J. T. (2011). Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study. BMC Complementary and Alternative Medicine, 11:78. PMID: 21939549; PMC3198755.
  5. Chang, S. M., & Chen, C. H. (2016). Effects of an intervention with drinking chamomile tea on sleep quality and depression in sleep disturbed postnatal women. Journal of Advanced Nursing, 72(2), 306–315.
  6. Godos, J., Ferri, R., Castellano, S., et al. (2020). Dietary polyphenol intake and sleep quality in a Mediterranean cohort. Nutrients, 12(5), 1226.
  7. Shinjyo, N., Waddell, G., & Green, J. (2024). Apigenin: a natural molecule at the intersection of sleep and aging. Frontiers in Nutrition, 11:1359176. PMC10929570.
  8. Synergistic sleep-promoting effects of magnesium and apigenin in normal and insomnia mouse models. (2026). Food & Function (RSC Publishing). DOI: 10.1039/D5FO04538J.
  9. Avallone, R., Zanoli, P., Puia, G., et al. (2000). Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla. Biochemical Pharmacology, 59(11), 1387–1394.
  10. Jager, A. K., Gauguin, B., Andersen, J., et al. (2006). Bioassay-guided isolation of apigenin with GABA-benzodiazepine activity from Tanacetum parthenium. Phytotherapy Research, 20(1), 1003–1005.
  11. WO1995005169A1 — Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity. University of Strathclyde (1993). [Expired]
  12. US9056209B2 — Apigenin-containing composition. Kao Corporation (2010/2015). [Expired — dermatological, not GABAergic therapeutic use]
  13. US20120213842A1 — Methods of making and using compositions comprising flavonoids (2012).
  14. US20070122495A1 — Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative (2007).
  15. 35 U.S.C. § 102 — Conditions for patentability; novelty.
  16. MPEP § 2131 — Anticipation — Application of 35 U.S.C. § 102.
  17. MPEP § 2121 — Prior Art; General Level of Operability Required to Make a Prima Facie Case.